UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16

UNDER THE SECURITIES EXCHANGE ACT of 1934

 

For the month of April 2016

 

001-37521

(Commission File Number)

 

INTEC PHARMA LTD.

(Translation of registrant’s name into English)

 

12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel

(+972) (2) 586-4657

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F  Form 40-F 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________

 

On April 21, 2016, Intec Pharma Ltd. (the “Company”) announced the results of its Special General Meeting of Shareholders (the “Meeting”) held on April 21, 2016.  At the Meeting, the Company’s shareholders voted on Proposal Nos. 1 and 2, as further detailed in the Company’s proxy statement for the Meeting, furnished on Form 6-K to the Securities and Exchange Commission on March 25, 2016, as amended on April 14, 2016.  Each matter voted upon was approved.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

  INTEC PHARMA LTD.  
       
  By: /s/ Zeev Weiss  
    Name: Zeev Weiss  
   

Title: Chief Executive Officer

 

 Date: April 21, 2016